NIOX Group (NIOX Group) Gross-Profit-to-Asset % : 27.37% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is NIOX Group Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. NIOX Group's annualized Gross Profit for the quarter that ended in Dec. 2023 was $32.41 Mil. NIOX Group's average Total Assets over the quarter that ended in Dec. 2023 was $118.39 Mil. Therefore, NIOX Group's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 27.37%.

NIOX Group Gross-Profit-to-Asset % Historical Data

The historical data trend for NIOX Group's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NIOX Group Gross-Profit-to-Asset % Chart

NIOX Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

9.38

9.48

19.94

23.03

28.45

NIOX Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															20.13	23.72	23.37	28.72	27.37

Competitive Comparison of NIOX Group's Gross-Profit-to-Asset %

For the Medical Devices subindustry, NIOX Group's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NIOX Group's Gross-Profit-to-Asset % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where NIOX Group's Gross-Profit-to-Asset % falls into.

NIOX Group Gross-Profit-to-Asset % Calculation

NIOX Group's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	33.544	/	( (119.976	+	115.823)	/ 2 )
	=	33.544	/	117.8995
	=	28.45 %

NIOX Group's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	32.406	/	( (120.96	+	115.823)	/ 2 )
	=	32.406	/	118.3915
	=	27.37 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

NIOX Group Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of NIOX Group's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

NIOX Group (NIOX Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NIOX Group PLC (OTCPK:CSSPF) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

NIOX:UK 82C:Germany

Address

Edmund Halley Road, Hayakawa Building, The Oxford Science Park, Oxford, GBR, OX4 4GB

Website

https://investors.niox.com

NIOX Group PLC is a medical device company that develops a range of therapies for asthma, chronic obstructive pulmonary disease, and allergy. The company has a single operating segment: NIOX. The NIOX segment relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO). Geographically, it derives a majority of its revenue from the Asia Pacific and also has a presence in the European Union, the United States, the United Kingdom, and the Rest of the world.